Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Issue Cover for Volume 28, Number 11—November 2022

Volume 28, Number 11—November 2022

[PDF - 25.68 MB - 226 pages]

Synopses

Medscape CME Activity
Severe Pneumonia Caused by Corynebacterium striatum in Adults, Seoul, South Korea, 2014–2019 [PDF - 632 KB - 8 pages]
Y. Lee et al.

We investigated the proportion and characteristics of severe Corynebacterium striatum pneumonia in South Korea during 2014–2019. As part of an ongoing observational study of severe pneumonia among adult patients, we identified 27 severe C. striatum pneumonia cases. Most (70.4%) cases were hospital-acquired, and 51.9% of patients were immunocompromised. C. striatum cases among patients with severe hospital-acquired pneumonia (HAP) increased from 1.0% (2/200) during 2014–2015 to 5.4% (10/185) during 2018–2019, but methicillin-resistant Staphylococcus aureus (MRSA) infections among severe HAP cases decreased from 12.0% to 2.7% during the same timeframe. During 2018–2019, C. striatum was responsible for 13.3% of severe HAP cases from which bacterial pathogens were identified. The 90-day mortality rates were similarly high in the C. striatum and MRSA groups. C. striatum was a major cause of severe HAP and had high mortality rates. This pathogen is emerging as a possible cause for severe pneumonia, especially among immunocompromised patients.

EID Lee Y, Huh J, Hong S, Jung J, Kim M, Chong Y, et al. Severe Pneumonia Caused by Corynebacterium striatum in Adults, Seoul, South Korea, 2014–2019. Emerg Infect Dis. 2022;28(11):2147-2154. https://doi.org/10.3201/eid2811.220273
AMA Lee Y, Huh J, Hong S, et al. Severe Pneumonia Caused by Corynebacterium striatum in Adults, Seoul, South Korea, 2014–2019. Emerging Infectious Diseases. 2022;28(11):2147-2154. doi:10.3201/eid2811.220273.
APA Lee, Y., Huh, J., Hong, S., Jung, J., Kim, M., Chong, Y....Choi, S. (2022). Severe Pneumonia Caused by Corynebacterium striatum in Adults, Seoul, South Korea, 2014–2019. Emerging Infectious Diseases, 28(11), 2147-2154. https://doi.org/10.3201/eid2811.220273.

Medscape CME Activity
Multispecies Outbreak of Nocardia Infections in Heart Transplant Recipients and Association with Climate Conditions, Australia [PDF - 2.28 MB - 10 pages]
J. Li et al.

A multispecies outbreak of Nocardia occurred among heart transplant recipients (HTR), but not lung transplant recipients (LTR), in Sydney, New South Wales, Australia, during 2018–2019. We performed a retrospective review of 23 HTR and LTR who had Nocardia spp. infections during June 2015–March 2021, compared risk factors for Nocardia infection, and evaluated climate conditions before, during, and after the period of the 2018–2019 outbreak. Compared with LTR, HTR had a shorter median time from transplant to Nocardia diagnosis, higher prevalence of diabetes, greater use of induction immunosuppression with basiliximab, and increased rates of cellular rejection before Nocardia diagnosis. During the outbreak, Sydney experienced the lowest monthly precipitation and driest surface levels compared with time periods directly before and after the outbreak. Increased immunosuppression of HTR compared with LTR, coupled with extreme weather conditions during 2018–2019, may explain this outbreak of Nocardia infections in HTR.

EID Li J, Lau C, Anderson N, Burrows F, Mirdad F, Carlos L, et al. Multispecies Outbreak of Nocardia Infections in Heart Transplant Recipients and Association with Climate Conditions, Australia. Emerg Infect Dis. 2022;28(11):2155-2164. https://doi.org/10.3201/eid2811.220262
AMA Li J, Lau C, Anderson N, et al. Multispecies Outbreak of Nocardia Infections in Heart Transplant Recipients and Association with Climate Conditions, Australia. Emerging Infectious Diseases. 2022;28(11):2155-2164. doi:10.3201/eid2811.220262.
APA Li, J., Lau, C., Anderson, N., Burrows, F., Mirdad, F., Carlos, L....Dharan, N. J. (2022). Multispecies Outbreak of Nocardia Infections in Heart Transplant Recipients and Association with Climate Conditions, Australia. Emerging Infectious Diseases, 28(11), 2155-2164. https://doi.org/10.3201/eid2811.220262.
Research

Effectiveness of Second mRNA COVID-19 Booster Vaccine in Immunocompromised Persons and Long-Term Care Facility Residents [PDF - 867 KB - 6 pages]
Y. Kim et al.

We used a nationwide population registry in South Korea to estimate the effect of a second booster dose of mRNA COVID-19 vaccine on the risk for laboratory-confirmed SARS-CoV-2 infection, critical infection, and death in immunocompromised persons and long-term care facility (LTCF) residents. During February 16–May 7, 2022, among 972,449 eligible persons, 736,439 (75.7%) received a first booster and 236,010 (24.3%) persons received a second booster. Compared with the first booster group, at 30–53 days, the second booster recipients had vaccine effectiveness (VE) against all infections of 22.28% (95% CI 19.35%–25.11%), VE against critical infection of 56.95% (95% CI 29.99%–73.53%), and VE against death of 62.96% (95% CI 34.18%–79.15%). Our findings provide real-world evidence that a second booster dose of mRNA vaccine substantially increases protection against critical infection and death in these high-risk population groups.

EID Kim Y, Choe Y, Kim J, Kim R, Jang E, Park S, et al. Effectiveness of Second mRNA COVID-19 Booster Vaccine in Immunocompromised Persons and Long-Term Care Facility Residents. Emerg Infect Dis. 2022;28(11):2165-2170. https://doi.org/10.3201/eid2811.220918
AMA Kim Y, Choe Y, Kim J, et al. Effectiveness of Second mRNA COVID-19 Booster Vaccine in Immunocompromised Persons and Long-Term Care Facility Residents. Emerging Infectious Diseases. 2022;28(11):2165-2170. doi:10.3201/eid2811.220918.
APA Kim, Y., Choe, Y., Kim, J., Kim, R., Jang, E., Park, S....Park, Y. (2022). Effectiveness of Second mRNA COVID-19 Booster Vaccine in Immunocompromised Persons and Long-Term Care Facility Residents. Emerging Infectious Diseases, 28(11), 2165-2170. https://doi.org/10.3201/eid2811.220918.

Racial/Ethnic Disparities in Exposure, Disease Susceptibility, and Clinical Outcomes during COVID-19 Pandemic in National Cohort of Adults, United States [PDF - 734 KB - 10 pages]
M. M. Robertson et al.

We examined racial/ethnic disparities for COVID-19 seroconversion and hospitalization within a prospective cohort (n = 6,740) in the United States enrolled in March 2020 and followed-up through October 2021. Potential SARS-CoV-2 exposure, susceptibility to COVID-19 complications, and access to healthcare varied by race/ethnicity. Hispanic and Black non-Hispanic participants had more exposure risk and difficulty with healthcare access than white participants. Participants with more exposure had greater odds of seroconversion. Participants with more susceptibility and more barriers to healthcare had greater odds of hospitalization. Race/ethnicity positively modified the association between susceptibility and hospitalization. Findings might help to explain the disproportionate burden of SARS-CoV-2 infections and complications among Hispanic/Latino/a and Black non-Hispanic persons. Primary and secondary prevention efforts should address disparities in exposure, vaccination, and treatment for COVID-19.

EID Robertson MM, Shamsunder MG, Brazier E, Mantravadi M, Zimba R, Rane MS, et al. Racial/Ethnic Disparities in Exposure, Disease Susceptibility, and Clinical Outcomes during COVID-19 Pandemic in National Cohort of Adults, United States. Emerg Infect Dis. 2022;28(11):2171-2180. https://doi.org/10.3201/eid2811.220072
AMA Robertson MM, Shamsunder MG, Brazier E, et al. Racial/Ethnic Disparities in Exposure, Disease Susceptibility, and Clinical Outcomes during COVID-19 Pandemic in National Cohort of Adults, United States. Emerging Infectious Diseases. 2022;28(11):2171-2180. doi:10.3201/eid2811.220072.
APA Robertson, M. M., Shamsunder, M. G., Brazier, E., Mantravadi, M., Zimba, R., Rane, M. S....Nash, D. (2022). Racial/Ethnic Disparities in Exposure, Disease Susceptibility, and Clinical Outcomes during COVID-19 Pandemic in National Cohort of Adults, United States. Emerging Infectious Diseases, 28(11), 2171-2180. https://doi.org/10.3201/eid2811.220072.

Effects of the COVID-19 Pandemic on Incidence and Epidemiology of Catheter-Related Bacteremia, Spain [PDF - 1.43 MB - 9 pages]
O. Gasch et al.

We compared hospital-acquired catheter-related bacteremia (CRB) episodes diagnosed at acute care hospitals in Catalonia, Spain, during the COVID-19 pandemic in 2020 with those detected during 2007–2019. We compared the annual observed and predicted CRB rates by using the negative binomial regression model and calculated stratified annual root mean squared errors. A total of 10,030 episodes were diagnosed during 2007–2020. During 2020, the observed CRB incidence rate was 0.29/103 patient-days, whereas the predicted CRB rate was 0.14/103 patient-days. The root mean squared error was 0.153. Thus, a substantial increase in hospital-acquired CRB cases was observed during the COVID-19 pandemic in 2020 compared with the rate predicted from 2007–2019. The incidence rate was expected to increase by 1.07 (95% CI 1–1.15) for every 1,000 COVID-19–related hospital admissions. We recommend maintaining all CRB prevention efforts regardless of the coexistence of other challenges, such as the COVID-19 pandemic.

EID Gasch O, Badia-Cebada L, Carmezim J, Vaqué M, Pomar V, Moreno E, et al. Effects of the COVID-19 Pandemic on Incidence and Epidemiology of Catheter-Related Bacteremia, Spain. Emerg Infect Dis. 2022;28(11):2181-2189. https://doi.org/10.3201/eid2811.220547
AMA Gasch O, Badia-Cebada L, Carmezim J, et al. Effects of the COVID-19 Pandemic on Incidence and Epidemiology of Catheter-Related Bacteremia, Spain. Emerging Infectious Diseases. 2022;28(11):2181-2189. doi:10.3201/eid2811.220547.
APA Gasch, O., Badia-Cebada, L., Carmezim, J., Vaqué, M., Pomar, V., Moreno, E....Pujol, M. (2022). Effects of the COVID-19 Pandemic on Incidence and Epidemiology of Catheter-Related Bacteremia, Spain. Emerging Infectious Diseases, 28(11), 2181-2189. https://doi.org/10.3201/eid2811.220547.

Invasive Infections Caused by Lancefield Groups C/G and A Streptococcus, Western Australia, Australia, 2000–2018 [PDF - 667 KB - 8 pages]
C. M. Wright et al.

Epidemiologic data on invasive group C/G Streptococcus (iGCGS) infections are sparse internationally. Linked population-level hospital, pathology, and death data were used to describe the disease burden in Western Australia, Australia, during 2000–2018 compared with that of invasive group A Streptococcus (GAS, Streptococcus pyogenes) infections. Of 1,270 cases, 866 (68%) occurred in men. Patients with iGCGS infection were older (median age 62 years) than those with invasive GAS (median age 44 years; p<0.0001). The age and sex-adjusted incidence rate ratio by year was 1.08 (95% CI 1.07–1.09). The incidence rate ratio for Indigenous compared with non-Indigenous Australians was 3.6 (95% CI 3.0–4.3). The all-cause 90-day death rate was 9% for iGCGS infection compared with 7% for invasive GAS (p = 0.03). iGCGS infection was more common in men and older persons and had a higher death rate, perhaps reflecting the effect of age and comorbidities on incidence and death.

EID Wright CM, Moorin R, Pearson G, Dyer J, Carapetis J, Manning L. Invasive Infections Caused by Lancefield Groups C/G and A Streptococcus, Western Australia, Australia, 2000–2018. Emerg Infect Dis. 2022;28(11):2190-2197. https://doi.org/10.3201/eid2811.220029
AMA Wright CM, Moorin R, Pearson G, et al. Invasive Infections Caused by Lancefield Groups C/G and A Streptococcus, Western Australia, Australia, 2000–2018. Emerging Infectious Diseases. 2022;28(11):2190-2197. doi:10.3201/eid2811.220029.
APA Wright, C. M., Moorin, R., Pearson, G., Dyer, J., Carapetis, J., & Manning, L. (2022). Invasive Infections Caused by Lancefield Groups C/G and A Streptococcus, Western Australia, Australia, 2000–2018. Emerging Infectious Diseases, 28(11), 2190-2197. https://doi.org/10.3201/eid2811.220029.

Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020–March 2022 [PDF - 2.93 MB - 8 pages]
S. Yamayoshi et al.

Japan has reported a relatively small number of COVID-19 cases. Because not all infected persons receive diagnostic tests for COVID-19, the reported number must be lower than the actual number of infections. We assessed SARS-CoV-2 seroprevalence by analyzing >60,000 samples collected in Japan (Tokyo Metropolitan Area and Hokkaido Prefecture) during February 2020–March 2022. The results showed that ≈3.8% of the population had become seropositive by January 2021. The seroprevalence increased with the administration of vaccinations; however, among the elderly, seroprevalence was not as high as the vaccination rate. Among children, who were not eligible for vaccination, infection was spread during the epidemic waves caused by the SARS-CoV-2 Delta and Omicron variants. Nevertheless, seroprevalence for unvaccinated children <5 years of age was as low as 10% as of March 2022. Our study underscores the low incidence of SARS-CoV-2 infection in Japan and the effects of vaccination on immunity at the population level.

EID Yamayoshi S, Iwatsuki-Horimoto K, Okuda M, Ujie M, Yasuhara A, Murakami J, et al. Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020–March 2022. Emerg Infect Dis. 2022;28(11):2198-2205. https://doi.org/10.3201/eid2811.221127
AMA Yamayoshi S, Iwatsuki-Horimoto K, Okuda M, et al. Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020–March 2022. Emerging Infectious Diseases. 2022;28(11):2198-2205. doi:10.3201/eid2811.221127.
APA Yamayoshi, S., Iwatsuki-Horimoto, K., Okuda, M., Ujie, M., Yasuhara, A., Murakami, J....Furuse, Y. (2022). Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020–March 2022. Emerging Infectious Diseases, 28(11), 2198-2205. https://doi.org/10.3201/eid2811.221127.

Spatiotemporal Patterns of Anthrax, Vietnam, 1990–2015 [PDF - 2.48 MB - 8 pages]
M. A. Walker et al.

Anthrax is a priority zoonosis for control in Vietnam. The geographic distribution of anthrax remains to be defined, challenging our ability to target areas for control. We analyzed human anthrax cases in Vietnam to obtain anthrax incidence at the national and provincial level. Nationally, the trendline for cases remained at ≈61 cases/year throughout the 26 years of available data, indicating control efforts are not effectively reducing disease burden over time. Most anthrax cases occurred in the Northern Midlands and Mountainous regions, and the provinces of Lai Chau, Dien Bien, Lao Cai, Ha Giang, Cao Bang, and Son La experienced some of the highest incidence rates. Based on spatial Bayes smoothed maps, every region of Vietnam experienced human anthrax cases during the study period. Clarifying the distribution of anthrax in Vietnam will enable us to better identify risk areas for improved surveillance, rapid clinical care, and livestock vaccination campaigns.

EID Walker MA, Tan L, Dang L, Van Khang P, Ha H, Hung T, et al. Spatiotemporal Patterns of Anthrax, Vietnam, 1990–2015. Emerg Infect Dis. 2022;28(11):2206-2213. https://doi.org/10.3201/eid2811.212584
AMA Walker MA, Tan L, Dang L, et al. Spatiotemporal Patterns of Anthrax, Vietnam, 1990–2015. Emerging Infectious Diseases. 2022;28(11):2206-2213. doi:10.3201/eid2811.212584.
APA Walker, M. A., Tan, L., Dang, L., Van Khang, P., Ha, H., Hung, T....Blackburn, J. K. (2022). Spatiotemporal Patterns of Anthrax, Vietnam, 1990–2015. Emerging Infectious Diseases, 28(11), 2206-2213. https://doi.org/10.3201/eid2811.212584.

Coronavirus Antibody Responses before COVID-19 Pandemic, Africa and Thailand [PDF - 4.37 MB - 12 pages]
Y. Li et al.

Prior immune responses to coronaviruses might affect human SARS-CoV-2 response. We screened 2,565 serum and plasma samples collected from 2013 through early 2020, before the COVID-19 pandemic began, from 2,250 persons in 4 countries in Africa (Kenya, Nigeria, Tanzania, and Uganda) and in Thailand, including persons living with HIV-1. We detected IgG responses to SARS-CoV-2 spike (S) subunit 2 protein in 1.8% of participants. Profiling against 23 coronavirus antigens revealed that responses to S, subunit 2, or subunit 1 proteins were significantly more frequent than responses to the receptor-binding domain, S-Trimer, or nucleocapsid proteins (p<0.0001). We observed similar responses in persons with or without HIV-1. Among all coronavirus antigens tested, SARS-CoV-2, SARS-CoV-1, and Middle East respiratory syndrome coronavirus antibody responses were much higher in participants from Africa than in participants from Thailand (p<0.01). We noted less pronounced differences for endemic coronaviruses. Serosurveys could affect vaccine and monoclonal antibody distribution across global populations.

EID Li Y, Merbah M, Wollen-Roberts S, Beckman B, Mdluli T, Swafford I, et al. Coronavirus Antibody Responses before COVID-19 Pandemic, Africa and Thailand. Emerg Infect Dis. 2022;28(11):2214-2225. https://doi.org/10.3201/eid2811.221041
AMA Li Y, Merbah M, Wollen-Roberts S, et al. Coronavirus Antibody Responses before COVID-19 Pandemic, Africa and Thailand. Emerging Infectious Diseases. 2022;28(11):2214-2225. doi:10.3201/eid2811.221041.
APA Li, Y., Merbah, M., Wollen-Roberts, S., Beckman, B., Mdluli, T., Swafford, I....Rolland, M. (2022). Coronavirus Antibody Responses before COVID-19 Pandemic, Africa and Thailand. Emerging Infectious Diseases, 28(11), 2214-2225. https://doi.org/10.3201/eid2811.221041.

Fungal Endophthalmitis Outbreak after Cataract Surgery, South Korea, 2020 [PDF - 2.31 MB - 8 pages]
S. Yoon et al.

In November 2020, an unusual increase in fungal endophthalmitis cases after cataract surgery was reported to the Korea Disease Control and Prevention Agency, South Korea. We initiated an outbreak investigation to identify the cause. We identified 156 cases nationwide, 62 confirmed and 94 probable. Most case-patients were exposed during surgery to ocular viscoelastic devices (OVDs) from the same manufacturer (company A). We isolated Fusarium spp. from 50 confirmed cases. Molecular identification of 39 fungal isolates from clinical samples and 13 isolates from OVDs confirmed F. oxysporum caused the infections. The risk ratio for fungal endophthalmitis from company A’s OVDs was 86.0 (95% CI 27.4–256.9), much higher than risk from other manufacturers’ products. We determined this fungal endophthalmitis outbreak was caused by a contaminated lot of OVDs and recommended discontinued use of this product. Early recognition of outbreaks and joint responses from related government agencies can reduce risk for fungal endophthalmitis.

EID Yoon S, Kim S, Bahk H, Ahn Y, Lee J, Kim H, et al. Fungal Endophthalmitis Outbreak after Cataract Surgery, South Korea, 2020. Emerg Infect Dis. 2022;28(11):2226-2233. https://doi.org/10.3201/eid2811.220361
AMA Yoon S, Kim S, Bahk H, et al. Fungal Endophthalmitis Outbreak after Cataract Surgery, South Korea, 2020. Emerging Infectious Diseases. 2022;28(11):2226-2233. doi:10.3201/eid2811.220361.
APA Yoon, S., Kim, S., Bahk, H., Ahn, Y., Lee, J., Kim, H....Lee, Y. (2022). Fungal Endophthalmitis Outbreak after Cataract Surgery, South Korea, 2020. Emerging Infectious Diseases, 28(11), 2226-2233. https://doi.org/10.3201/eid2811.220361.

Incidence, Etiology, and Healthcare Utilization for Acute Gastroenteritis in the Community, United States [PDF - 934 KB - 9 pages]
M. A. Schmidt et al.

Knowledge of the epidemiology of sporadic acute gastroenteritis (AGE) in the United States is limited. During September 2016–September 2017, we surveyed Kaiser Permanente Northwest members in Oregon and Washington, USA, to collect data on the 30-day prevalence of dually defined AGE and diarrhea disease and related health-seeking behavior; from a subset of participants, we obtained a stool specimen. Using the iterative proportional fitting algorithm with raked weights, we generated AGE prevalence and annualized rate estimates. We detected norovirus, rotavirus, astrovirus, and sapovirus from submitted stool specimens through real-time quantitative reverse transcription PCR (qRT-PCR). We estimated a 30-day prevalence of 10.4% for AGE and 7.6% for diarrhea only; annual rates were 1.27 cases/person/year for AGE and 0.92 cases/person/year for diarrhea only. Of those with AGE, 19% sought medical care. Almost one quarter (22.4%) of stool specimens from those reporting AGE tested positive for ≥1 viral pathogen, compared with 8.2% from those without AGE.

EID Schmidt MA, Groom HC, Rawlings AM, Mattison CP, Salas SB, Burke RM, et al. Incidence, Etiology, and Healthcare Utilization for Acute Gastroenteritis in the Community, United States. Emerg Infect Dis. 2022;28(11):2234-2242. https://doi.org/10.3201/eid2811.220247
AMA Schmidt MA, Groom HC, Rawlings AM, et al. Incidence, Etiology, and Healthcare Utilization for Acute Gastroenteritis in the Community, United States. Emerging Infectious Diseases. 2022;28(11):2234-2242. doi:10.3201/eid2811.220247.
APA Schmidt, M. A., Groom, H. C., Rawlings, A. M., Mattison, C. P., Salas, S. B., Burke, R. M....Hall, A. J. (2022). Incidence, Etiology, and Healthcare Utilization for Acute Gastroenteritis in the Community, United States. Emerging Infectious Diseases, 28(11), 2234-2242. https://doi.org/10.3201/eid2811.220247.

Socioeconomic Inequalities in COVID-19 Vaccination and Infection in Adults, Catalonia, Spain [PDF - 1.26 MB - 10 pages]
E. Roel et al.

Evidence on the impact of the COVID-19 vaccine rollout on socioeconomic COVID-19–related inequalities is scarce. We analyzed associations between socioeconomic deprivation index (SDI) and COVID-19 vaccination, infection, and hospitalization before and after vaccine rollout in Catalonia, Spain. We conducted a population-based cohort study during September 2020–June 2021 that comprised 2,297,146 adults >40 years of age. We estimated odds ratio of nonvaccination and hazard ratios (HRs) of infection and hospitalization by SDI quintile relative to the least deprived quintile, Q1. Six months after rollout, vaccination coverage differed by SDI quintile in working-age (40–64 years) persons: 81% for Q1, 71% for Q5. Before rollout, we found a pattern of increased HR of infection and hospitalization with deprivation among working-age and retirement-age (>65 years) persons. After rollout, infection inequalities decreased in both age groups, whereas hospitalization inequalities decreased among retirement-age persons. Our findings suggest that mass vaccination reduced socioeconomic COVID-19–related inequalities.

EID Roel E, Raventós B, Burn E, Pistillo A, Prieto-Alhambra D, Duarte-Salles T. Socioeconomic Inequalities in COVID-19 Vaccination and Infection in Adults, Catalonia, Spain. Emerg Infect Dis. 2022;28(11):2243-2252. https://doi.org/10.3201/eid2811.220614
AMA Roel E, Raventós B, Burn E, et al. Socioeconomic Inequalities in COVID-19 Vaccination and Infection in Adults, Catalonia, Spain. Emerging Infectious Diseases. 2022;28(11):2243-2252. doi:10.3201/eid2811.220614.
APA Roel, E., Raventós, B., Burn, E., Pistillo, A., Prieto-Alhambra, D., & Duarte-Salles, T. (2022). Socioeconomic Inequalities in COVID-19 Vaccination and Infection in Adults, Catalonia, Spain. Emerging Infectious Diseases, 28(11), 2243-2252. https://doi.org/10.3201/eid2811.220614.

Genomic Epidemiology of Vibrio cholerae O139, Zhejiang Province, China, 1994–2018 [PDF - 1.09 MB - 8 pages]
Y. Luo et al.

Cholera caused by Vibrio cholerae O139 was first reported in Bangladesh and India in 1992. To determine the genomic epidemiology and origins of O139 in China, we sequenced 104 O139 isolates collected from Zhejiang Province, China, during 1994–2018 and compared them with 57 O139 genomes from other countries in Asia. Most Zhejiang isolates fell into 3 clusters (C1–C3), which probably originated in India (C1) and Thailand (C2 and C3) during the early 1990s. Different clusters harbored different antimicrobial resistance genes and IncA/C plasmids. The integrative and conjugative elements carried by Zhejiang isolates were of a new type, differing from ICEVchInd4 and SXTMO10 by single-nucleotide polymorphisms and presence of genes. Quinolone resistance–conferring mutations S85L in parC and S83I in gyrA occurred in 71.2% of the Zhejiang isolates. The ctxB copy number differed among the 3 clusters. Our findings provided new insights for prevention and control of O139 cholera .

EID Luo Y, Ye J, Payne M, Hu D, Jiang J, Lan R. Genomic Epidemiology of Vibrio cholerae O139, Zhejiang Province, China, 1994–2018. Emerg Infect Dis. 2022;28(11):2253-2260. https://doi.org/10.3201/eid2811.212066
AMA Luo Y, Ye J, Payne M, et al. Genomic Epidemiology of Vibrio cholerae O139, Zhejiang Province, China, 1994–2018. Emerging Infectious Diseases. 2022;28(11):2253-2260. doi:10.3201/eid2811.212066.
APA Luo, Y., Ye, J., Payne, M., Hu, D., Jiang, J., & Lan, R. (2022). Genomic Epidemiology of Vibrio cholerae O139, Zhejiang Province, China, 1994–2018. Emerging Infectious Diseases, 28(11), 2253-2260. https://doi.org/10.3201/eid2811.212066.

Prevalence of Histoplasmosis among Persons with Advanced HIV Disease, Nigeria [PDF - 963 KB - 9 pages]
R. O. Oladele et al.

We sought to determine the prevalence of probable disseminated histoplasmosis among advanced HIV disease (AHD) patients in Nigeria. We conducted a cross-sectional study in 10 sites across 5 of 6 geopolitical zones in Nigeria. We identified patients with CD4 cell counts <200 cells/mm3 or World Health Organization stage 3 or 4 disease who also had >2 clinical features of disseminated histoplasmosis, and we tested them for Histoplasma antigen using a Histoplasma enzyme immune assay. Of 988 participants we recruited, 76 (7.7%) were antigen-positive. The 76 Histoplasma antigen–positive participants had significantly lower (p = 0.03) CD4 counts; 9 (11.8%) were also co-infected with tuberculosis. Most antigen-positive participants (50/76; 65.8%; p = 0.015) had previously received antiretroviral treatment; 26/76 (34.2%) had not. Because histoplasmosis is often a hidden disease among AHD patients in Nigeria, Histoplasma antigen testing should be required in the AHD package of care.

EID Oladele RO, Osaigbovo II, Akanmu AS, Adekanmbi OA, Ekeng BE, Mohammed Y, et al. Prevalence of Histoplasmosis among Persons with Advanced HIV Disease, Nigeria. Emerg Infect Dis. 2022;28(11):2261-2269. https://doi.org/10.3201/eid2811.220542
AMA Oladele RO, Osaigbovo II, Akanmu AS, et al. Prevalence of Histoplasmosis among Persons with Advanced HIV Disease, Nigeria. Emerging Infectious Diseases. 2022;28(11):2261-2269. doi:10.3201/eid2811.220542.
APA Oladele, R. O., Osaigbovo, I. I., Akanmu, A. S., Adekanmbi, O. A., Ekeng, B. E., Mohammed, Y....Chiller, T. (2022). Prevalence of Histoplasmosis among Persons with Advanced HIV Disease, Nigeria. Emerging Infectious Diseases, 28(11), 2261-2269. https://doi.org/10.3201/eid2811.220542.

Differences in SARS-CoV-2 Clinical Manifestations and Disease Severity in Children and Adolescents by Infecting Variant [PDF - 1.52 MB - 11 pages]
A. Quintero et al.

Since the COVID-19 pandemic began, different SARS-CoV-2 variants have been identified and associated with higher transmissibility than the ancestral nonvariant strain. During January 1, 2021–January 15, 2022, we assessed differences in clinical and viral parameters in a convenience sample of COVID-19 outpatients and inpatients 0–21 years of age in Columbus, Ohio, USA, according to the infecting variant, identified using a mutation-specific reverse transcription PCR assay. Of the 676 patients in the study, 17.75% were infected with nonvariant strains, 18.49% with the Alpha variant, 41.72% with Delta, and 16.42% with Omicron. Rates of SARS-COV-2/viral co-infections were 15.66%–29.41% and were comparable across infecting variants. Inpatients with acute Delta and Omicron infections had lower SARS-CoV-2 cycle threshold values and more frequent fever and respiratory symptoms than those with nonvariant strain infections. In addition, SARS-COV-2/viral co-infections and the presence of underlying conditions were independently associated with worse clinical outcomes, irrespective of the infecting variant.

EID Quintero A, Eisner M, Sayegh R, Wright T, Ramilo O, Leber AL, et al. Differences in SARS-CoV-2 Clinical Manifestations and Disease Severity in Children and Adolescents by Infecting Variant. Emerg Infect Dis. 2022;28(11):2270-2280. https://doi.org/10.3201/eid2811.220577
AMA Quintero A, Eisner M, Sayegh R, et al. Differences in SARS-CoV-2 Clinical Manifestations and Disease Severity in Children and Adolescents by Infecting Variant. Emerging Infectious Diseases. 2022;28(11):2270-2280. doi:10.3201/eid2811.220577.
APA Quintero, A., Eisner, M., Sayegh, R., Wright, T., Ramilo, O., Leber, A. L....Mejias, A. (2022). Differences in SARS-CoV-2 Clinical Manifestations and Disease Severity in Children and Adolescents by Infecting Variant. Emerging Infectious Diseases, 28(11), 2270-2280. https://doi.org/10.3201/eid2811.220577.
Dispatches

Imported Haycocknema perplexum Infection, United States [PDF - 1.88 MB - 4 pages]
B. S. Pritt et al.

We report an imported case of myositis caused by a rare parasite, Haycocknema perplexum, in Australia in a 37-year-old man who had progressive facial, axial, and limb weakness, dysphagia, dysphonia, increased levels of creatine kinase and hepatic aminotransferases, and peripheral eosinophilia for 8 years. He was given extended, high-dose albendazole.

EID Pritt BS, Mathison BA, Bradbury RS, Liewluck T, Nicolau S, O’Horo JC, et al. Imported Haycocknema perplexum Infection, United States. Emerg Infect Dis. 2022;28(11):2281-2284. https://doi.org/10.3201/eid2811.220286
AMA Pritt BS, Mathison BA, Bradbury RS, et al. Imported Haycocknema perplexum Infection, United States. Emerging Infectious Diseases. 2022;28(11):2281-2284. doi:10.3201/eid2811.220286.
APA Pritt, B. S., Mathison, B. A., Bradbury, R. S., Liewluck, T., Nicolau, S., O’Horo, J. C....Virk, A. (2022). Imported Haycocknema perplexum Infection, United States. Emerging Infectious Diseases, 28(11), 2281-2284. https://doi.org/10.3201/eid2811.220286.

Deaths Related to Chagas Disease and COVID-19 Co-Infection, Brazil, March–December 2020 [PDF - 1.22 MB - 5 pages]
F. R. Martins-Melo et al.

We analyzed epidemiologic characteristics and distribution of 492 deaths related to Chagas disease and coronavirus disease (COVID-19) co-infection in Brazil during March‒December 2020. Cumulative co-infected death rates were highest among advanced age groups, persons of Afro-Brazilian ethnicity and with low education levels, and geographically distributed mainly in major Chagas disease‒endemic areas.

EID Martins-Melo FR, Castro MC, Ribeiro AP, Heukelbach J, Werneck GL. Deaths Related to Chagas Disease and COVID-19 Co-Infection, Brazil, March–December 2020. Emerg Infect Dis. 2022;28(11):2285-2289. https://doi.org/10.3201/eid2811.212158
AMA Martins-Melo FR, Castro MC, Ribeiro AP, et al. Deaths Related to Chagas Disease and COVID-19 Co-Infection, Brazil, March–December 2020. Emerging Infectious Diseases. 2022;28(11):2285-2289. doi:10.3201/eid2811.212158.
APA Martins-Melo, F. R., Castro, M. C., Ribeiro, A. P., Heukelbach, J., & Werneck, G. L. (2022). Deaths Related to Chagas Disease and COVID-19 Co-Infection, Brazil, March–December 2020. Emerging Infectious Diseases, 28(11), 2285-2289. https://doi.org/10.3201/eid2811.212158.

Rift Valley Fever Outbreak during COVID-19 Surge, Uganda, 2021 [PDF - 1.66 MB - 4 pages]
C. M. Cossaboom et al.

Rift Valley fever, endemic or emerging throughout most of Africa, causes considerable risk to human and animal health. We report 7 confirmed Rift Valley fever cases, 1 fatal, in Kiruhura District, Uganda, during 2021. Our findings highlight the importance of continued viral hemorrhagic fever surveillance, despite challenges associated with the COVID-19 pandemic.

EID Cossaboom CM, Nyakarahuka L, Mulei S, Kyondo J, Tumusiime A, Baluku J, et al. Rift Valley Fever Outbreak during COVID-19 Surge, Uganda, 2021. Emerg Infect Dis. 2022;28(11):2290-2293. https://doi.org/10.3201/eid2811.220364
AMA Cossaboom CM, Nyakarahuka L, Mulei S, et al. Rift Valley Fever Outbreak during COVID-19 Surge, Uganda, 2021. Emerging Infectious Diseases. 2022;28(11):2290-2293. doi:10.3201/eid2811.220364.
APA Cossaboom, C. M., Nyakarahuka, L., Mulei, S., Kyondo, J., Tumusiime, A., Baluku, J....Shoemaker, T. (2022). Rift Valley Fever Outbreak during COVID-19 Surge, Uganda, 2021. Emerging Infectious Diseases, 28(11), 2290-2293. https://doi.org/10.3201/eid2811.220364.

COVID-19 among Chronic Dialysis Patients after First Year of Pandemic, Argentina [PDF - 1.05 MB - 4 pages]
A. Vallejos et al.

We performed a descriptive study to characterize effects from COVID-19 among chronic dialysis patients compared with the general population in Argentina during March 2020–February 2021. COVID-19 case-fatality rate of chronic dialysis patients was 10 times the national rate; the age-standardized mortality ratio was 6.8 (95% CI 6.3–7.3).

EID Vallejos A, Baldani A, Gauto MA, Rueda DV, Santoro FM, Abriata M. COVID-19 among Chronic Dialysis Patients after First Year of Pandemic, Argentina. Emerg Infect Dis. 2022;28(11):2294-2297. https://doi.org/10.3201/eid2811.212597
AMA Vallejos A, Baldani A, Gauto MA, et al. COVID-19 among Chronic Dialysis Patients after First Year of Pandemic, Argentina. Emerging Infectious Diseases. 2022;28(11):2294-2297. doi:10.3201/eid2811.212597.
APA Vallejos, A., Baldani, A., Gauto, M. A., Rueda, D. V., Santoro, F. M., & Abriata, M. (2022). COVID-19 among Chronic Dialysis Patients after First Year of Pandemic, Argentina. Emerging Infectious Diseases, 28(11), 2294-2297. https://doi.org/10.3201/eid2811.212597.

Molecular Detection of Haplorchis pumilio Eggs in Schoolchildren, Kome Island, Lake Victoria, Tanzania [PDF - 1.44 MB - 4 pages]
H. Shin et al.

A survey of intestinal helminths targeting 1,440 schoolchildren in 12 primary schools on Kome Island (Lake Victoria), Tanzania, revealed small trematode eggs in 19 children (1.3%), seemingly of a species of Haplorchis or Heterophyes. The eggs were molecularly confirmed to be Haplorchis pumilio on the basis of 18S and 28S rDNA sequences.

EID Shin H, Jung B, Ryoo S, Hong S, Jeong H, Jeoung H, et al. Molecular Detection of Haplorchis pumilio Eggs in Schoolchildren, Kome Island, Lake Victoria, Tanzania. Emerg Infect Dis. 2022;28(11):2298-2301. https://doi.org/10.3201/eid2811.220653
AMA Shin H, Jung B, Ryoo S, et al. Molecular Detection of Haplorchis pumilio Eggs in Schoolchildren, Kome Island, Lake Victoria, Tanzania. Emerging Infectious Diseases. 2022;28(11):2298-2301. doi:10.3201/eid2811.220653.
APA Shin, H., Jung, B., Ryoo, S., Hong, S., Jeong, H., Jeoung, H....Chai, J. (2022). Molecular Detection of Haplorchis pumilio Eggs in Schoolchildren, Kome Island, Lake Victoria, Tanzania. Emerging Infectious Diseases, 28(11), 2298-2301. https://doi.org/10.3201/eid2811.220653.

Polyclonal Dissemination of OXA-232 Carbapenemase–Producing Klebsiella pneumoniae, France, 2013–2021 [PDF - 1.62 MB - 4 pages]
C. Emeraud et al.

During 2013–2021, increased prevalence of oxacillinase 232–producing Enterobacterales was observed in France, mostly driven by its emergence in Klebsiella pneumoniae. Whole-genome sequencing identified that oxacillinase 232–producing K. pneumoniae belonged to 14 sequence types (STs), among which 2 polyclonal high-risk clones, ST-231 and ST-2096, were overrepresented.

EID Emeraud C, Birer A, Girlich D, Jousset AB, Creton E, Naas T, et al. Polyclonal Dissemination of OXA-232 Carbapenemase–Producing Klebsiella pneumoniae, France, 2013–2021. Emerg Infect Dis. 2022;28(11):2304-2307. https://doi.org/10.3201/eid2811.221040
AMA Emeraud C, Birer A, Girlich D, et al. Polyclonal Dissemination of OXA-232 Carbapenemase–Producing Klebsiella pneumoniae, France, 2013–2021. Emerging Infectious Diseases. 2022;28(11):2304-2307. doi:10.3201/eid2811.221040.
APA Emeraud, C., Birer, A., Girlich, D., Jousset, A. B., Creton, E., Naas, T....Dortet, L. (2022). Polyclonal Dissemination of OXA-232 Carbapenemase–Producing Klebsiella pneumoniae, France, 2013–2021. Emerging Infectious Diseases, 28(11), 2304-2307. https://doi.org/10.3201/eid2811.221040.

Sequence-Based Identification of Metronidazole-Resistant Clostridioides difficile Isolates [PDF - 922 KB - 4 pages]
W. Smits et al.

The plasmid pCD-METRO confers metronidazole resistance in Clostridioides difficile. We showed high sequence similarity among pCD-METRO plasmids from different isolates and identified pCD-METRO and associated metronidazole-resistant isolates in clinical and veterinary reservoirs in the Americas. We recommend using PCR or genomic assays to detect pCD-METRO in metronidazole-resistant C. difficile.

EID Smits W, Harmanus C, Sanders I, Bry L, Blackwell GA, Ducarmon QR, et al. Sequence-Based Identification of Metronidazole-Resistant Clostridioides difficile Isolates. Emerg Infect Dis. 2022;28(11):2308-2311. https://doi.org/10.3201/eid2811.220615
AMA Smits W, Harmanus C, Sanders I, et al. Sequence-Based Identification of Metronidazole-Resistant Clostridioides difficile Isolates. Emerging Infectious Diseases. 2022;28(11):2308-2311. doi:10.3201/eid2811.220615.
APA Smits, W., Harmanus, C., Sanders, I., Bry, L., Blackwell, G. A., Ducarmon, Q. R....Kuijper, E. (2022). Sequence-Based Identification of Metronidazole-Resistant Clostridioides difficile Isolates. Emerging Infectious Diseases, 28(11), 2308-2311. https://doi.org/10.3201/eid2811.220615.

Cluster of Norovirus Genogroup IX Outbreaks in Long-Term Care Facilities, Utah, USA, 2021 [PDF - 1.06 MB - 4 pages]
B. Osborn et al.

We report 5 clustered acute gastroenteritis outbreaks in long-term care facilities in Utah, USA, that were linked to healthcare employees working at multiple facilities. Four outbreaks were caused by norovirus genotype GIX. We recommend continued norovirus surveillance and genotyping to determine contributions of this genotype to norovirus outbreaks.

EID Osborn B, Pan C, Hatada A, Hatfield J, Wagner J, Oakeson K, et al. Cluster of Norovirus Genogroup IX Outbreaks in Long-Term Care Facilities, Utah, USA, 2021. Emerg Infect Dis. 2022;28(11):2312-2315. https://doi.org/10.3201/eid2811.220842
AMA Osborn B, Pan C, Hatada A, et al. Cluster of Norovirus Genogroup IX Outbreaks in Long-Term Care Facilities, Utah, USA, 2021. Emerging Infectious Diseases. 2022;28(11):2312-2315. doi:10.3201/eid2811.220842.
APA Osborn, B., Pan, C., Hatada, A., Hatfield, J., Wagner, J., Oakeson, K....Vinjé, J. (2022). Cluster of Norovirus Genogroup IX Outbreaks in Long-Term Care Facilities, Utah, USA, 2021. Emerging Infectious Diseases, 28(11), 2312-2315. https://doi.org/10.3201/eid2811.220842.

Seroincidence of Enteric Fever, Juba, South Sudan [PDF - 1.30 MB - 5 pages]
K. Aiemjoy et al.

We applied a new serosurveillance tool to estimate typhoidal Salmonella burden using samples collected during 2020 from a population in Juba, South Sudan. By using dried blood spot testing, we found an enteric fever seroincidence rate of 30/100 person-years and cumulative incidence of 74% over a 4-year period.

EID Aiemjoy K, Rumunu J, Hassen J, Wiens KE, Garrett D, Kamenskaya P, et al. Seroincidence of Enteric Fever, Juba, South Sudan. Emerg Infect Dis. 2022;28(11):2316-2320. https://doi.org/10.3201/eid2811.220239
AMA Aiemjoy K, Rumunu J, Hassen J, et al. Seroincidence of Enteric Fever, Juba, South Sudan. Emerging Infectious Diseases. 2022;28(11):2316-2320. doi:10.3201/eid2811.220239.
APA Aiemjoy, K., Rumunu, J., Hassen, J., Wiens, K. E., Garrett, D., Kamenskaya, P....Charles, R. C. (2022). Seroincidence of Enteric Fever, Juba, South Sudan. Emerging Infectious Diseases, 28(11), 2316-2320. https://doi.org/10.3201/eid2811.220239.

Effect of COVID-19 Pandemic on Invasive Pneumococcal Disease in Children, Catalonia, Spain [PDF - 842 KB - 5 pages]
P. Ciruela et al.

We analyzed the effect of COVID-19 on healthcare demand and invasive pneumococcal disease in children in Catalonia, Spain. Compared with 2018–2019, we noted large reductions in healthcare activities and incidence of invasive pneumococcal disease in 2020. These changes likely resulted from nonpharmaceutical measures implemented during the COVID-19 pandemic.

EID Ciruela P, Soldevila N, García-Garcia J, González-Peris S, Díaz-Conradi A, Redin A, et al. Effect of COVID-19 Pandemic on Invasive Pneumococcal Disease in Children, Catalonia, Spain. Emerg Infect Dis. 2022;28(11):2321-2325. https://doi.org/10.3201/eid2811.211741
AMA Ciruela P, Soldevila N, García-Garcia J, et al. Effect of COVID-19 Pandemic on Invasive Pneumococcal Disease in Children, Catalonia, Spain. Emerging Infectious Diseases. 2022;28(11):2321-2325. doi:10.3201/eid2811.211741.
APA Ciruela, P., Soldevila, N., García-Garcia, J., González-Peris, S., Díaz-Conradi, A., Redin, A....Domínguez, A. (2022). Effect of COVID-19 Pandemic on Invasive Pneumococcal Disease in Children, Catalonia, Spain. Emerging Infectious Diseases, 28(11), 2321-2325. https://doi.org/10.3201/eid2811.211741.

Crimean-Congo Hemorrhagic Fever Outbreak in Refugee Settlement during COVID-19 Pandemic, Uganda, April 2021 [PDF - 1.44 MB - 4 pages]
L. Nyakarahuka et al.

Crimean-Congo hemorrhagic fever (CCHF) was detected in 2 refugees living in a refugee settlement in Kikuube district, Uganda. Investigations revealed a CCHF IgG seroprevalence of 71.3% (37/52) in goats within the refugee settlement. This finding highlights the need for a multisectoral approach to controlling CCHF in humans and animals in Uganda.

EID Nyakarahuka L, Whitmer S, Kyondo J, Mulei S, Cossaboom CM, Telford CT, et al. Crimean-Congo Hemorrhagic Fever Outbreak in Refugee Settlement during COVID-19 Pandemic, Uganda, April 2021. Emerg Infect Dis. 2022;28(11):2326-2329. https://doi.org/10.3201/eid2811.220365
AMA Nyakarahuka L, Whitmer S, Kyondo J, et al. Crimean-Congo Hemorrhagic Fever Outbreak in Refugee Settlement during COVID-19 Pandemic, Uganda, April 2021. Emerging Infectious Diseases. 2022;28(11):2326-2329. doi:10.3201/eid2811.220365.
APA Nyakarahuka, L., Whitmer, S., Kyondo, J., Mulei, S., Cossaboom, C. M., Telford, C. T....Klena, J. D. (2022). Crimean-Congo Hemorrhagic Fever Outbreak in Refugee Settlement during COVID-19 Pandemic, Uganda, April 2021. Emerging Infectious Diseases, 28(11), 2326-2329. https://doi.org/10.3201/eid2811.220365.

Jamestown Canyon Virus in Collected Mosquitoes, Maine, United States, 2017–2019 [PDF - 997 KB - 4 pages]
E. F. Schneider et al.

Jamestown Canyon virus (JCV) is a mosquito-borne arbovirus that circulates in North America. We detected JCV in 4 pools of mosquitoes collected from midcoastal Maine, USA, during 2017–2019. Phylogenetic analysis of a JCV sequence obtained from Aedes cantator mosquitoes clustered within clade A, which also circulates in Connecticut, USA.

EID Schneider EF, Robich RM, Elias SP, Lubelczyk CB, Cosenza DS, Smith RP. Jamestown Canyon Virus in Collected Mosquitoes, Maine, United States, 2017–2019. Emerg Infect Dis. 2022;28(11):2330-2333. https://doi.org/10.3201/eid2811.212382
AMA Schneider EF, Robich RM, Elias SP, et al. Jamestown Canyon Virus in Collected Mosquitoes, Maine, United States, 2017–2019. Emerging Infectious Diseases. 2022;28(11):2330-2333. doi:10.3201/eid2811.212382.
APA Schneider, E. F., Robich, R. M., Elias, S. P., Lubelczyk, C. B., Cosenza, D. S., & Smith, R. P. (2022). Jamestown Canyon Virus in Collected Mosquitoes, Maine, United States, 2017–2019. Emerging Infectious Diseases, 28(11), 2330-2333. https://doi.org/10.3201/eid2811.212382.
Research Letters

Monkeypox Virus Transmission to Healthcare Worker through Needlestick Injury, Brazil [PDF - 634 KB - 3 pages]
L. Carvalho et al.

We describe monkeypox virus (MPXV) transmission from a patient to a healthcare worker through needlestick injury. A lesion appeared at the inoculation site 5 days after injury. Blood tested MPXV-positive by PCR before symptoms worsened; blood remained MPXV-positive at discharge 19 days after symptom onset. Postexposure prophylaxis could prevent potential MPXV bloodborne transmission.

EID Carvalho L, Casadio L, Polly M, Nastri A, Turdo A, de Araujo Eliodoro RH, et al. Monkeypox Virus Transmission to Healthcare Worker through Needlestick Injury, Brazil. Emerg Infect Dis. 2022;28(11):2334-2336. https://doi.org/10.3201/eid2811.221323
AMA Carvalho L, Casadio L, Polly M, et al. Monkeypox Virus Transmission to Healthcare Worker through Needlestick Injury, Brazil. Emerging Infectious Diseases. 2022;28(11):2334-2336. doi:10.3201/eid2811.221323.
APA Carvalho, L., Casadio, L., Polly, M., Nastri, A., Turdo, A., de Araujo Eliodoro, R. H....Higashino, H. (2022). Monkeypox Virus Transmission to Healthcare Worker through Needlestick Injury, Brazil. Emerging Infectious Diseases, 28(11), 2334-2336. https://doi.org/10.3201/eid2811.221323.

Monkeypox in Patient Immunized with ACAM2000 Smallpox Vaccine During 2022 Outbreak [PDF - 615 KB - 3 pages]
M. Turner et al.

We report a case of monkeypox in the United States in a patient who had been vaccinated with ACAM2000 smallpox vaccine 8 years earlier. Despite his vaccination status, he still contracted disease. He showed prodromal symptoms preceding development of painless penile lesions that later coalesced.

EID Turner M, Mandia J, Keltner C, Haynes R, Faestel P, Mease L. Monkeypox in Patient Immunized with ACAM2000 Smallpox Vaccine During 2022 Outbreak. Emerg Infect Dis. 2022;28(11):2336-2338. https://doi.org/10.3201/eid2811.221215
AMA Turner M, Mandia J, Keltner C, et al. Monkeypox in Patient Immunized with ACAM2000 Smallpox Vaccine During 2022 Outbreak. Emerging Infectious Diseases. 2022;28(11):2336-2338. doi:10.3201/eid2811.221215.
APA Turner, M., Mandia, J., Keltner, C., Haynes, R., Faestel, P., & Mease, L. (2022). Monkeypox in Patient Immunized with ACAM2000 Smallpox Vaccine During 2022 Outbreak. Emerging Infectious Diseases, 28(11), 2336-2338. https://doi.org/10.3201/eid2811.221215.

Vaccine Effectiveness against SARS-CoV-2 Variant P.1 in Nursing-Facility Residents, Washington, USA, April 2021 [PDF - 333 KB - 4 pages]
J. W. Lewis et al.

A SARS-CoV-2 P.1 (Gamma) variant outbreak occurred at a skilled nursing facility in Washington, USA, in April 2021. Effectiveness of 2 doses of mRNA vaccines against P.1 infection among residents in this outbreak was 75.0% (95% CI 44.5%–88.7%), similar to effectiveness for other pre-Delta variants among long-term care residents.

EID Lewis JW, Loughran J, Deng L, Varghese J, Clark S, Harrison C, et al. Vaccine Effectiveness against SARS-CoV-2 Variant P.1 in Nursing-Facility Residents, Washington, USA, April 2021. Emerg Infect Dis. 2022;28(11):2338-2341. https://doi.org/10.3201/eid2811.221043
AMA Lewis JW, Loughran J, Deng L, et al. Vaccine Effectiveness against SARS-CoV-2 Variant P.1 in Nursing-Facility Residents, Washington, USA, April 2021. Emerging Infectious Diseases. 2022;28(11):2338-2341. doi:10.3201/eid2811.221043.
APA Lewis, J. W., Loughran, J., Deng, L., Varghese, J., Clark, S., Harrison, C....Fleming-Dutra, K. E. (2022). Vaccine Effectiveness against SARS-CoV-2 Variant P.1 in Nursing-Facility Residents, Washington, USA, April 2021. Emerging Infectious Diseases, 28(11), 2338-2341. https://doi.org/10.3201/eid2811.221043.

Reinfections with Different SARS-CoV-2 Omicron Subvariants, France [PDF - 463 KB - 3 pages]
N. Nguyen et al.

We describe 188 patients in France who were successively infected with different SARS-CoV-2 Omicron subvariants, including BA.1, BA.2, and BA.5. Time between 2 infections was <90 days for 50 (26.6%) patients and <60 days for 28 (14.9%) patients. This finding suggests that definitions for SARS-CoV-2 reinfection require revision.

EID Nguyen N, Houhamdi L, Delorme L, Colson P, Gautret P. Reinfections with Different SARS-CoV-2 Omicron Subvariants, France. Emerg Infect Dis. 2022;28(11):2341-2343. https://doi.org/10.3201/eid2811.221109
AMA Nguyen N, Houhamdi L, Delorme L, et al. Reinfections with Different SARS-CoV-2 Omicron Subvariants, France. Emerging Infectious Diseases. 2022;28(11):2341-2343. doi:10.3201/eid2811.221109.
APA Nguyen, N., Houhamdi, L., Delorme, L., Colson, P., & Gautret, P. (2022). Reinfections with Different SARS-CoV-2 Omicron Subvariants, France. Emerging Infectious Diseases, 28(11), 2341-2343. https://doi.org/10.3201/eid2811.221109.

Human Parainfluenza Virus in Homeless Shelters before and during the COVID-19 Pandemic, Washington, USA [PDF - 718 KB - 5 pages]
E. J. Chow et al.

To determine the epidemiology of human parainfluenza virus in homeless shelters during the COVID-19 pandemic, we analyzed data and sequences from respiratory specimens collected in 23 shelters in Washington, USA, during 2019–2021. Two clusters in children were genetically similar by shelter of origin. Shelter-specific interventions are needed to reduce these infections.

EID Chow EJ, Casto AM, Sampoleo R, Mills MG, Han PD, Xie H, et al. Human Parainfluenza Virus in Homeless Shelters before and during the COVID-19 Pandemic, Washington, USA. Emerg Infect Dis. 2022;28(11):2343-2347. https://doi.org/10.3201/eid2811.221156
AMA Chow EJ, Casto AM, Sampoleo R, et al. Human Parainfluenza Virus in Homeless Shelters before and during the COVID-19 Pandemic, Washington, USA. Emerging Infectious Diseases. 2022;28(11):2343-2347. doi:10.3201/eid2811.221156.
APA Chow, E. J., Casto, A. M., Sampoleo, R., Mills, M. G., Han, P. D., Xie, H....Chu, H. Y. (2022). Human Parainfluenza Virus in Homeless Shelters before and during the COVID-19 Pandemic, Washington, USA. Emerging Infectious Diseases, 28(11), 2343-2347. https://doi.org/10.3201/eid2811.221156.

Presence of Spirometra mansoni, Causative Agent of Sparganosis, in South America [PDF - 748 KB - 4 pages]
J. Brabec et al.

We report molecular identification of an adult Spirometra mansoni tapeworm retrieved from a crab-eating fox (Cerdocyon thous) in Colombia, confirming presence of this parasite in South America. This tapeworm is the causative agent of human sparganosis, commonly reported from Southeast Asia, and represents the second congeneric species with known zoonotic potential in the Americas.

EID Brabec J, Uribe M, Chaparro-Gutiérrez JJ, Hermosilla C. Presence of Spirometra mansoni, Causative Agent of Sparganosis, in South America. Emerg Infect Dis. 2022;28(11):2347-2350. https://doi.org/10.3201/eid2811.220529
AMA Brabec J, Uribe M, Chaparro-Gutiérrez JJ, et al. Presence of Spirometra mansoni, Causative Agent of Sparganosis, in South America. Emerging Infectious Diseases. 2022;28(11):2347-2350. doi:10.3201/eid2811.220529.
APA Brabec, J., Uribe, M., Chaparro-Gutiérrez, J. J., & Hermosilla, C. (2022). Presence of Spirometra mansoni, Causative Agent of Sparganosis, in South America. Emerging Infectious Diseases, 28(11), 2347-2350. https://doi.org/10.3201/eid2811.220529.

TIGIT Monoallelic Nonsense Variant in Patient with Severe COVID-19 Infection, Thailand [PDF - 517 KB - 3 pages]
P. Sodsai et al.

A heterozygous nonsense variant in the TIGIT gene was identified in a patient in Thailand who had severe COVID-19, resulting in lower TIGIT expression in T cells. The patient’s T cells produced higher levels of cytokines upon stimulation. This mutation causes less-controlled immune responses, which might contribute to COVID-19 severity.

EID Sodsai P, Ittiwut C, Ruenjaiman V, Ittiwut R, Jantarabenjakul W, Suphapeetiporn K, et al. TIGIT Monoallelic Nonsense Variant in Patient with Severe COVID-19 Infection, Thailand. Emerg Infect Dis. 2022;28(11):2350-2352. https://doi.org/10.3201/eid2811.220914
AMA Sodsai P, Ittiwut C, Ruenjaiman V, et al. TIGIT Monoallelic Nonsense Variant in Patient with Severe COVID-19 Infection, Thailand. Emerging Infectious Diseases. 2022;28(11):2350-2352. doi:10.3201/eid2811.220914.
APA Sodsai, P., Ittiwut, C., Ruenjaiman, V., Ittiwut, R., Jantarabenjakul, W., Suphapeetiporn, K....Hirankarn, N. (2022). TIGIT Monoallelic Nonsense Variant in Patient with Severe COVID-19 Infection, Thailand. Emerging Infectious Diseases, 28(11), 2350-2352. https://doi.org/10.3201/eid2811.220914.

SARS-CoV-2 Omicron BA.1 Challenge after Ancestral or Delta Infection in Mice [PDF - 763 KB - 4 pages]
M. Baz et al.

We assessed cross-reactivity to BA.1, BA.2, and BA.5 of neutralizing antibodies elicited by ancestral, Delta, and Omicron BA.1 SARS-CoV-2 infection in mice. Primary infection elicited homologous antibodies with poor cross-reactivity to Omicron strains. This pattern remained after BA.1 challenge, although ancestral- and Delta-infected mice were protected from BA.1 infection.

EID Baz M, Deshpande N, Mackenzie-Kludas C, Mordant F, Anderson D, Subbarao K. SARS-CoV-2 Omicron BA.1 Challenge after Ancestral or Delta Infection in Mice. Emerg Infect Dis. 2022;28(11):2352-2355. https://doi.org/10.3201/eid2811.220718
AMA Baz M, Deshpande N, Mackenzie-Kludas C, et al. SARS-CoV-2 Omicron BA.1 Challenge after Ancestral or Delta Infection in Mice. Emerging Infectious Diseases. 2022;28(11):2352-2355. doi:10.3201/eid2811.220718.
APA Baz, M., Deshpande, N., Mackenzie-Kludas, C., Mordant, F., Anderson, D., & Subbarao, K. (2022). SARS-CoV-2 Omicron BA.1 Challenge after Ancestral or Delta Infection in Mice. Emerging Infectious Diseases, 28(11), 2352-2355. https://doi.org/10.3201/eid2811.220718.

Serologic Evidence of Human Exposure to Ehrlichiosis Agents in Japan [PDF - 546 KB - 3 pages]
H. Su et al.

In retrospective analyses, we report 3 febrile patients in Japan who had seroconversion to antibodies against Ehrlichia chaffeensis antigens detected by using an immunofluorescence and Western blot. Our results provide evidence of autochthonous human ehrlichiosis cases and indicate ehrlichiosis should be considered a potential cause of febrile illness in Japan.

EID Su H, Kubo K, Sakabe S, Mizuno S, Komiya N, Akachi S, et al. Serologic Evidence of Human Exposure to Ehrlichiosis Agents in Japan. Emerg Infect Dis. 2022;28(11):2355-2357. https://doi.org/10.3201/eid2811.212566
AMA Su H, Kubo K, Sakabe S, et al. Serologic Evidence of Human Exposure to Ehrlichiosis Agents in Japan. Emerging Infectious Diseases. 2022;28(11):2355-2357. doi:10.3201/eid2811.212566.
APA Su, H., Kubo, K., Sakabe, S., Mizuno, S., Komiya, N., Akachi, S....Ohashi, N. (2022). Serologic Evidence of Human Exposure to Ehrlichiosis Agents in Japan. Emerging Infectious Diseases, 28(11), 2355-2357. https://doi.org/10.3201/eid2811.212566.

Environmental Investigation during Legionellosis Outbreak, Montérégie, Quebec, Canada, 2021 [PDF - 1.65 MB - 4 pages]
L. Atikessé et al.

In August 2021, a legionellosis outbreak involving 7 persons occurred within a 500-meter radius in the Montérégie region of Québec, Canada. Near real-time modeling of wind direction along with epidemiologic and environmental investigations identified the possible source. Modeling wind direction could help identify likely Legionella pneumophila sources during legionellosis outbreaks.

EID Atikessé L, Kadaoui N, Lavallée V, Levac É, St-Amour M, Milord F. Environmental Investigation during Legionellosis Outbreak, Montérégie, Quebec, Canada, 2021. Emerg Infect Dis. 2022;28(11):2357-2360. https://doi.org/10.3201/eid2811.220151
AMA Atikessé L, Kadaoui N, Lavallée V, et al. Environmental Investigation during Legionellosis Outbreak, Montérégie, Quebec, Canada, 2021. Emerging Infectious Diseases. 2022;28(11):2357-2360. doi:10.3201/eid2811.220151.
APA Atikessé, L., Kadaoui, N., Lavallée, V., Levac, É., St-Amour, M., & Milord, F. (2022). Environmental Investigation during Legionellosis Outbreak, Montérégie, Quebec, Canada, 2021. Emerging Infectious Diseases, 28(11), 2357-2360. https://doi.org/10.3201/eid2811.220151.
Etymologia

Etymologia: Pseudoterranova decipiens [PDF - 990 KB - 2 pages]
W. C. Partin and R. S. Bradbury
EID Partin WC, Bradbury RS. Etymologia: Pseudoterranova decipiens. Emerg Infect Dis. 2022;28(11):2302-2303. https://doi.org/10.3201/eid2811.220792
AMA Partin WC, Bradbury RS. Etymologia: Pseudoterranova decipiens. Emerging Infectious Diseases. 2022;28(11):2302-2303. doi:10.3201/eid2811.220792.
APA Partin, W. C., & Bradbury, R. S. (2022). Etymologia: Pseudoterranova decipiens. Emerging Infectious Diseases, 28(11), 2302-2303. https://doi.org/10.3201/eid2811.220792.
Online Reports

Increased Detection of Carbapenemase-Producing Enterobacterales Bacteria in Latin America and the Caribbean during the COVID-19 Pandemic [PDF - 537 KB - 8 pages]
G. Thomas et al.

During 2020–2021, countries in Latin America and the Caribbean reported clinical emergence of carbapenemase-producing Enterobacterales that had not been previously characterized locally, increased prevalence of carbapenemases that had previously been detected, and co-production of multiple carbapenemases in some isolates. These increases were likely fueled by changes related to the COVID-19 pandemic, including empirical antibiotic use for potential COVID-19–related bacterial infections and healthcare limitations resulting from the rapid rise in COVID-19 cases. Strengthening antimicrobial resistance surveillance, epidemiologic research, and infection prevention and control programs and antimicrobial stewardship in clinical settings can help prevent emergence and transmission of carbapenemase-producing Enterobacterales.

EID Thomas G, Corso A, Pasterán F, Shal J, Sosa A, Pillonetto M, et al. Increased Detection of Carbapenemase-Producing Enterobacterales Bacteria in Latin America and the Caribbean during the COVID-19 Pandemic. Emerg Infect Dis. 2022;28(11):1-8. https://doi.org/10.3201/eid2811.220415
AMA Thomas G, Corso A, Pasterán F, et al. Increased Detection of Carbapenemase-Producing Enterobacterales Bacteria in Latin America and the Caribbean during the COVID-19 Pandemic. Emerging Infectious Diseases. 2022;28(11):1-8. doi:10.3201/eid2811.220415.
APA Thomas, G., Corso, A., Pasterán, F., Shal, J., Sosa, A., Pillonetto, M....Melano, R. (2022). Increased Detection of Carbapenemase-Producing Enterobacterales Bacteria in Latin America and the Caribbean during the COVID-19 Pandemic. Emerging Infectious Diseases, 28(11), 1-8. https://doi.org/10.3201/eid2811.220415.
About the Cover

Flotsam of Never-Ending Respiratory Pathogens [PDF - 1.22 MB - 2 pages]
K. Gensheimer and B. Breedlove
EID Gensheimer K, Breedlove B. Flotsam of Never-Ending Respiratory Pathogens. Emerg Infect Dis. 2022;28(11):2361-2362. https://doi.org/10.3201/eid2811.ac2811
AMA Gensheimer K, Breedlove B. Flotsam of Never-Ending Respiratory Pathogens. Emerging Infectious Diseases. 2022;28(11):2361-2362. doi:10.3201/eid2811.ac2811.
APA Gensheimer, K., & Breedlove, B. (2022). Flotsam of Never-Ending Respiratory Pathogens. Emerging Infectious Diseases, 28(11), 2361-2362. https://doi.org/10.3201/eid2811.ac2811.
Page created: October 24, 2022
Page updated: October 24, 2022
Page reviewed: October 24, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
edit_01 ScholarOne Submission Portal
Issue Select
GO
GO

Spotlight Topics

 

Get Email Updates

To receive email updates about this page, enter your email address:

file_external